Mandate

Vinge advises Nordea and UBS in relation to Sanitec’s listing on NASDAQ OMX Stockholm

November 29, 2013

Vinge advises Nordea Bank AB (publ) and UBS Limited – joint global coordinators and bookrunners – in relation to Sanitec Oyj:s application for listing on NASDAQ OMX Stockholm. Sanitec’s principal shareholder is EQT. A prospectus was published on 27 November and the first day of trading on NASDAQ OMX Stockholm is expected to be 10 December.  

EQT may increase the offer and have also granted, among others, Nordea and UBS a customary over-allotment option. The total value of the offering amounts to approximately SEK 2.4 billion. Assuming the offering is increased in full, the total value of the offering amounts to approximately SEK 3.1 billion (and approximately SEK 3.6 billion assuming the over-allotment option is also exercised in full).  

Sanitec is the market leader in bathroom ceramics and a leading supplier of bathroom fixtures in its core markets (Belgium, Denmark, Finland, France, Germany, Italy, the Netherlands, Norway, Poland, Russia, Sweden, Ukraine, and the United Kingdom). Sanitec has leading positions (number one or two based on volume) in bathroom ceramics in 12 of its 13 core markets and command a strong position in growth markets, including Russia. Sanitec’s unique brand portfolio includes many of the longest-established and most well-known brands on the European bathroom fixtures market, including its ‘‘national jewels’’: Ifö® (Sweden and Denmark), Ido® (Finland and Sweden), Keramag® (Germany), Sphinx® (the Netherlands), Twyford® (United Kingdom), Allia® (France), Pozzi-Ginori® (Italy), Kolo® (Poland) and Colombo® (Ukraine). In 2012, Sanitec’s net sales amounted to EUR 752.8 million and the number of employees amounted to approximately 6,500.  

Vinge’s team consisted mainly of Peter Bäärnhielm and David Andersson.

Related

Vinge has advised Orexo in connection with the divestment of the US rights to Zubsolv

Vinge has advised Orexo in relation to Swedish law in connection with the divestment of the US rights to Zubsolv to Dexcel Pharma USA.
January 14, 2026

Vinge advises Revivo Group on acquisition of Haapanen

Revivo Group, a comprehensive provider of qualified surface treatment services, has acquired Haapanen, a well-established Finnish specialist company.
January 14, 2026

Vinge advises Morrow Bank in connection with cross-border merger and list change from Oslo Børs to Nasdaq Stockholm

Vinge has advised Morrow Bank in connection with its reverse cross-border merger, whereby Morrow Bank AB is taking over Morrow Bank ASA. The Norwegian bank was previously listed on the Oslo Stock Exchange which was today transferred to Nasdaq Stockholm. Vinge has previously assisted Morrow Bank in obtaining a Swedish banking licence.
January 12, 2026